Life-extension drugs

Life-extension drugs



Dimebon is a new revolutionary anti-Alzheimer's drug with unique mechanism of action.

Dimebon is a new revolutionary anti-Alzheimer's drug with unique mechanism of action.

Dimebolin hydrochloride (brand name Dimebon) is an antihistamine drug which has been used clinically in Russia since 1983. Research is continuing in both Russia and western nations into potential applications as a neuroprotective and potential nootropic. It is an active small molecule that has been shown to inhibit brain cell death in preclinical studies of Alzheimer's disease and Huntington's disease, making it a potential treatment for these and other neurodegenerative diseases. Research suggests that it may also have cognition-enhancing effects in healthy individuals, in the absence of neurodegenerative disease pathology

Generic name: dimebolin, Product Brand Name: Dimebon (to be marketed in USA as Latrepirdine by Pfizer after 2010-2011). Already marketed in Russia under brand name Dimebon. See also: Dimebolin

Citation from Sam Gandy, MD, PhD, Chairman Emeritus, US Alzheimer’s
Association, 11th International Conference on Alzheimer’s Disease 2008 in Chicago: "Diagnostics and therapeutics move forward despite some disappointments".

".....Giving ‘bap’ a run for the money in getting across the finish line for approval by the US Food and Drug Administration is the surprisingly well-performing drug Dimebon (dimebolin hydrochloride). This compound has a complicated history that is probably unrelated to its effect in Alzheimer’s, including antihistamine properties, cholinesterase inhibitor properties, and glutamate receptor blocking properties. The effect in Alzheimer’s seems too potent to be explained by any of these, so that is something to be worked on.

In the meantime, there is much experience with this drug (Dimebon) in Russia, and its safety profile is very favourable. Its benefits are startling: cognitive function in Alzheimer’s is claimed to improve for several months and then, as we heard at ICAD, stabilize for up to 18 months at the improved level.

This is better than anything that we currently have on the market. The US California biotech company Medivation is developing Dimebon, and this is certainly one to watch!...."

news archive...


My BasketMy Basket news news

Newsletter subscription

Product search

Product list

You are located on a secure website.
Customer data is for our internal use only and will be treated as confidential.

eXTReMe Tracker